Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Marinella Clerico; Stefania Federica De Mercanti; Alessio Signori; Marco Iudicello; Cinzia Cordioli; Elisabetta Signoriello; Giacomo Lus; Simona Bonavita; Luigi Lavorgna; Giorgia Teresa Maniscalco; Maria Pia Sormani; Ruggero Capra

doi:https://doi.org/10.1007/s13311-019-00776-7

doi.org/10.1007/s13311-019-00776-7

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Marinella Clerico

27

,

Stefania Federica De Mercanti

14

,

..., Ruggero Capra

36

Neurotherapeutics5.70

Volume: 17, Issue: 1, Pages: 200 - 207

Published: Jan 1, 2020

Abstract

Extending the natalizumab interval after the 24th administration could reduce the risk of progressive multifocal leukoencephalopathy (PML). The objective is to evaluate the noninferiority of the efficacy of an extended interval dosing (EID) compared with the standard interval dosing (SID) of natalizumab. It is an observational, multicenter (14 Italian centers), retrospective cohort study, starting from the 24th natalizumab infusion to the loss...